Invitrogen Promotes European General Manager to Senior Vice President of Sales for Europe and the Americas

Invitrogen Corporation (Nasdaq:IVGN), a leader in life science research, today promoted Bernd Brust to the newly created position of Senior Vice President of Sales for Europe and the Americas. In this new role, Brust will be responsible for leading the company’s Europe and Americas sales strategy, including optimizing direct sales force levels, customer relationship development and identifying new customer segments and regions that provide opportunity for future growth. "Bernd was instrumental in creating a winning go-to-market strategy in Europe, successfully optimizing the strategic mix of direct marketing, web presence, and sales force execution to consistently grow his region every quarter,” said Gregory T. Lucier, Chairman and CEO. "We have the right formula in Europe, where we are currently growing at strong high single digit rates. Our work now is to bring that same discipline and playbook to the Americas. Bernd has the talent and experience to do that.” Brust joined the company in 2004 and currently serves as General Manager and Vice President of European Operations. He has more than 15 years of sales, commercial operations and management experience. Prior to joining Invitrogen he served as General Manager Sales & Marketing for GE Medical Systems Information Technologies, where he was awarded GE Medical Systems IT Commercial Leader of the Year. Brust holds a bachelors degree in Engineering from THS in Amsterdam and is Six Sigma Green Belt certified. He will report directly to Chairman and CEO Greg Lucier. Susan Lambert, current VP of European Sales, will be assuming the General Manager and Vice President of European Operations role immediately. Susan joined the company in 1975 as part of European Operations, holding various levels of leadership positions within sales and marketing. The current general manager for North American Operations has decided to leave the company to pursue other interests. About Invitrogen Corporation Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com. Safe Harbor Statement Certain statements contained in this press release and in today’s conference call are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Such statements include, but are not limited to statements regarding Invitrogen’s: 1) financial projections, including revenue and pro forma earnings per share; 2) plans to address underperforming businesses in our portfolio; 3) momentum in 2006; 4) ability to generate new products that will accelerate scientific research and our future growth; 5) integration of acquired businesses; 6) plans to repurchase the Company’s Common Stock or Convertible Notes; and 7) plans to optimize expenses and increase operating margins. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to a) the Company’s ability to identify promising technology and new product development opportunities; b) the Company’s ability to identify and implement measures to effect cost savings and efficiency improvements; and c) the Company’s ability to identify acquisitions and organic growth opportunities that will position it to serve growing markets, as well as other risks and uncertainties detailed from time to time in Invitrogen’s Securities and Exchange Commission filings. For additional information regarding this announcement, please contact: